Innate Pharma gains anti-C5AR1 mAb from Novo Nordisk

Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) granted Innate Pharma S.A. (Euronext:IPH) exclusive, worldwide rights to develop and commercialize cancer candidate IPH5401.

IPH5401 is an antibody against complement receptor 5A (C5AR1; C5AR; CD88). Innate plans on beginning Phase I trials to treat cancer next year. Novo had conducted two Phase I trials with IPH5401 to treat rheumatoid arthritis (RA). Novo referred inquiries to Innate who declined to disclose additional details. ...